Proxy Results (Form 8-K)

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 17, 2026, Hepion Pharmaceuticals, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Meeting").

As of April 28, 2026, the record date for the Meeting, there were 29,119,476 shares of our common stock outstanding (including 85,581 shares of common stock issuable upon conversion of the Series A Preferred Stock).

At the Meeting, the stockholders voted on the following three proposals and cast their votes as follows:

1. To elect the five (5) persons named herein as nominees for directors of the Company, to hold office until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified consisting of Gary Stetz, Vincent LoPriore, Michael Purcell, Sireesh Appajosyula and Chase LoPriore.

2. To ratify the appointment of Grassi & Co., CPAs, P.C, as the Company's independent auditors for the fiscal year ending December 31, 2026.

3. To approve an amendment to the Company's 2023 Omnibus Equity Incentive Plan to increase the number of shares issuable thereunder to 8,000,000 from 200,000.